David Krempa - 11 Dec 2025 Form 4 Insider Report for Eton Pharmaceuticals, Inc. (ETON)

Signature
/s/ James R. Gruber
Issuer symbol
ETON
Transactions as of
11 Dec 2025
Transactions value $
-$106,488
Form type
4
Filing time
12 Dec 2025, 16:56:45 UTC
Previous filing
16 Jun 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Krempa David Chief Business Officer C/O ETON PHARMACEUTICALS, INC., 21925 W. FIELD PARKWAY, SUITE 235, DEERPARK /s/ James R. Gruber 12 Dec 2025 0001968254

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ETON Common Stock Tax liability -$106K -6.26K -0.98% $17.00 632K 12 Dec 2025 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ETON Restricted Stock Units Award $0 +5.3K +0.84% $0.00 638K 11 Dec 2025 Common Stock 5.3K Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units.
F2 The shares were sold in multiple trades at prices ranging from $16.83 to $17.11. The price reported above reflects the weighted average sales price.
F3 The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
F4 Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.
F5 The restricted stock units vest immediately as of the award date.

Remarks:

The Reporting Person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.